PRF Technologies (PRFX) Cash from Financing Activities (2020 - 2023)
PRF Technologies (PRFX) posted quarterly Cash from Financing Activities of $1.0 million for Q4 2023, down 71.56% on a QoQ basis from $3.6 million in Q3 2023.
PRF Technologies (PRFX) Cash from Financing Activities (2020 - 2023) Analysis & Trends
PRF Technologies (PRFX) has reported Cash from Financing Activities for 3 consecutive years, with $1.0 million the latest figure, recorded in Q4 2023.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $1.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $6.5 million (changed N/A YoY) and the FY2025 annual result came in at $3.8 million, down 56.92% from the prior year.
- Cash from Financing Activities retreated to $1.0 million in Q4 2023 per PRFX's latest filing, from $3.6 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for PRFX reached as high as $7.5 billion in Q3 2021 and fell as low as -$7.5 billion in Q4 2021.
- A 3-year average of $4.9 million and a median of $4.6 million in 2021 frame the typical range for Cash from Financing Activities.
- The largest YoY upside for Cash from Financing Activities was 42899.34% in 2021 against a maximum downside of 42899.34% in 2021.
- Year by year, Cash from Financing Activities stood at $17.4 million in 2020, then sank by 43088.25% to -$7.5 billion in 2021, then soared by 100.01% to $1.0 million in 2023.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.0 million, $3.6 million, and -$7.5 billion for Q4 2023, Q3 2023, and Q4 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.02 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Dec 31, 2021 | -7.48 Bn |
| Dec 31, 2021 | -7.48 Bn |
| Sep 30, 2021 | 7.48 Bn |
| Sep 30, 2021 | 7.48 Bn |
| Mar 31, 2021 | 5.55 Mn |
| Mar 31, 2021 | 5.55 Mn |
| Sep 30, 2020 | 17.39 Mn |
| Sep 30, 2020 | 17.39 Mn |